$CVRX News

CVRx Announces Humana Medicare Advantage Coverage Policy For The Company's Barostim Therapy, Effective May 1

CVRX Inc (NASDAQ:CVRX) Q1 2026 Earnings Meet Revenue Estimates, Loss Slightly Narrower Than Expected

CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript

CVRx Affirms FY2026 Sales Guidance of $63.000M-$67.000M vs $65.119M Est.

CVRx Sees Q2 Sales $15.100M-$16.100M vs $15.661M Est.

CVRx Q1 EPS $(0.50) Beats $(0.52) Estimate, Sales $14.769M Beat $14.481M Estimate.

CVRx Enrolls First Participant In BENEFIT-HF Study To Evaluate Barostim

CVRx Reports Preliminary Q1 Revenue Range $14.7M - $14.8M, Up From $12.3M YoY

CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

CVRx Announces Barostim Data To Be Revealed During Technology and Heart Failure Therapeutics 2026

CVRx Announces Barostim Data To Be Revealed During Technology and Heart Failure Therapeutics 2026

CVRx shares are trading higher after a Form 4 filing showed its Director purchased 46,800 shares at an average price of $6.36.

CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ...

Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results

CVRx shares are trading lower after Canaccord Genuity lowered its price target on the stock from $11 to $10.

Canaccord Genuity Maintains Buy on CVRx, Lowers Price Target to $10

CVRx, Inc. Q4 2025 Earnings Call Summary

CVRX Inc (NASDAQ:CVRX) Reports Mixed Q4 2025 Results, Slight EPS Miss

CVRx Q4 Earnings Call Highlights

CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript